Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efficacy and tolerance of Beriplex P/N in reversing oral anticoagulation
2005-000382-19Phase 3Completed
- Sponsor
- CSL Behring
- Start
- Jun 2005
- Modality
- Blood Coagulation Factors → Therapeutic Enzymes → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, single-arm trial of balfaxar in warfarin-induced coagulopathy, sponsored by CSL Behring. Primary endpoints: Rapid INR decrease and Increase in coagulation factor and protein C levels. Started Jun 2005; status: completed.
02
Drugs
balfaxar
03
Conditions
warfarin-induced coagulopathy
Beyond the preview
Go deeper on 2005-000382-19.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-000382-19.